Welcome to our dedicated page for Serina Therapeutics news (Ticker: ser), a resource for investors and traders seeking the latest updates and insights on Serina Therapeutics stock.
Serina Therapeutics Inc (SER) is a clinical-stage biotechnology innovator advancing neurological and pain therapies through its proprietary POZ Platform technology. This page serves as the definitive source for official company announcements, research milestones, and financial updates.
Investors and industry observers will find timely updates on clinical trial progress, regulatory developments, and strategic partnerships. Our curated collection includes press releases on drug candidate advancements, peer-reviewed research findings, and executive commentary – all essential for understanding SER's position in biopharmaceutical innovation.
Key focus areas include updates on the POZ Platform's application in drug delivery systems, trial phase transitions, and collaborative research initiatives. Content is organized to provide clear context about how each development aligns with the company's mission to improve neurological and pain management therapies.
Bookmark this page for direct access to primary source materials from Serina Therapeutics. Check regularly for new insights into the company's scientific advancements and operational milestones in the competitive biotech landscape.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company developing SER-252 for advanced Parkinson's disease, has granted stock options to a new non-executive employee. The inducement grant consists of options to purchase 12,500 shares of common stock, with an exercise price matching the closing price on June 18, 2025.
The Option Grant, approved by Serina's Compensation Committee under the 2024 Inducement Equity Plan, aims to align employee interests with stockholders and was made in compliance with NYSE American's Company Guide Section 711(a).
Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company, has announced its 2025 Annual Stockholders Meeting will be held on November 7, 2025. The specific time and location will be detailed in the company's definitive proxy statement to be filed with the SEC.
Due to the meeting date change of more than 30 days from the 2024 annual meeting anniversary, stockholder proposals under Rule 14a-8 must be submitted by 5:00 p.m. (Central Time) on August 15, 2025. For stockholder proposals and director nominations under the company's bylaws, submissions must be received between July 10, 2025, and August 9, 2025 at the company's Huntsville, Alabama headquarters.
Serina Therapeutics (NYSE American: SER) announced its CEO Steve Ledger will present at a FORCE Family Office investor webinar on June 26, 2025, at 12:00 p.m. ET. The presentation, titled "New Drug Optimization Platform to Transform Parkinson's Care," will focus on the company's drug candidate SER-252, a polymer conjugate of apomorphine designed to provide continuous dopaminergic stimulation for Parkinson's disease treatment.
The webinar will highlight the company's POZ Platform™ technology and its potential to improve safety, duration, and tolerability of Parkinson's treatments. The event will include a Q&A session hosted by FORCE Family Office CEO Steve Saltzstein.
Serina Therapeutics (NYSE: SER) has appointed Dr. Stephen Brannan to its Board of Directors. Dr. Brannan brings over 30 years of experience in neuroscience and neuropsychiatry drug development. He most recently served as Chief Medical Officer at Karuna Therapeutics, where he led the clinical development of KarXT, the first new schizophrenia treatment mechanism in over 30 years, which contributed to Karuna's $14 billion acquisition by Bristol Myers Squibb in 2024.
Dr. Brannan's extensive experience includes senior leadership roles at Takeda, Novartis, Cyberonics, and Eli Lilly, where he directed clinical programs in various CNS conditions. He will support Serina's strategic development of long-acting CNS therapeutics using their proprietary POZ Platform™ technology. The company also announced the departure of Remy Gross from its Board, who will continue supporting the team in a consulting role.
Serina Therapeutics (NYSE: SER), a clinical-stage biotech company developing SER-252 for advanced Parkinson's disease, has granted stock options to two new non-executive employees. The grants, totaling 15,000 shares of common stock, were made on March 20, 2025, with an exercise price matching the closing stock price on that date.
The Option Grants, approved by Serina's Compensation Committee under the 2024 Inducement Equity Plan, will vest over four years: 25% after the first year and the remaining 75% in three equal annual installments, subject to continued employment. These grants were made as employment inducements in compliance with NYSE American's Company Guide Section 711(a).
Serina's proprietary POZ Platform™ technology enables drug optimization for their lead candidate.Serina Therapeutics, a clinical-stage biotech company listed on NYSE American under ticker SER, has announced its participation in the upcoming JonesResearch Virtual CNS Day. The company, known for developing the proprietary POZ Platform™ drug optimization technology, will be represented by CEO Steve Ledger in a fireside chat presentation.
The virtual event is scheduled for April 29, 2025, at 12:00 p.m. EDT. Registered attendees can access the live webcast through a provided Zoom link. For those unable to attend the live session, an archived replay will remain available on-demand for 90 days after the event.